{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:57:22Z","timestamp":1777294642302,"version":"3.51.4"},"reference-count":43,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate the efficacy of oral spironolactone in patients with acute central serous chorioretinopathy (CSC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a prospective, randomised controlled clinical study. Thirty patients with acute CSC were the participants, including 18 patients who were treated with spironolactone (40\u2009mg orally, twice daily) for 2\u2009months in the experimental group and 12 patients who received observation in the control group. Main outcome measures included the proportion of eyes achieving complete resolution of subretinal fluid (SRF), changes in central macular thickness (CMT), the height of SRF (SRFH), best corrected visual acuity (BCVA) and subfoveal choroidal thickness (SFCT). The follow-up period was 2 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Complete resolution of SRF was achieved in 55.6% (10\/18) and 8.3% (1\/12) of the eyes in the treatment group and the control group, respectively, at 2 months (p=0.018). The mean CMT and SRFH decreased significantly at each visit in both groups (p&lt;0.05), and there was significant difference between the two groups at 2 months (p&lt;0.05 and p&lt;0.05, respectively). BCVA (in logarithm of the minimum angle of resolution; mean) improved in both groups at 2 months (p&lt;0.05). In the treatment group, the mean baseline SFCT significantly decreased from 502.50\u00b187.38\u2009\u00b5m to 427.44\u00b174.37\u2009\u00b5m at 2 months (p&lt;0.01), while the change from baseline (from 480.33\u00b1102.38\u2009\u00b5m to 463.75\u00b1100.63\u2009\u00b5m) was not significant in the control group (p=0.195). But the differences between the two groups in BCVA and SFCT were not significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Oral spironolactone is more effective with a faster absorption of SRF than observations. It is a promising treatment for acute CSC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=14155\" ext-link-type=\"uri\">ChiCTR-IPR-16008428<\/jats:ext-link>, Results.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-311096","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T16:17:25Z","timestamp":1509466645000},"page":"1060-1065","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Spironolactone versus observation in the treatment of acute central serous chorioretinopathy"],"prefix":"10.1136","volume":"102","author":[{"given":"Xinghong","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanlu","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangyi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizhong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songtao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,10,31]]},"reference":[{"key":"2020050713014875000_102.8.1060.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.02.032"},{"key":"2020050713014875000_102.8.1060.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2012.02848.x"},{"key":"2020050713014875000_102.8.1060.3","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1097\/IAE.0000000000001443","article-title":"Acute central serous chorioretinopathy: factors influencing episode duration","volume":"37","author":"Daruich","year":"2017","journal-title":"Retina"},{"key":"2020050713014875000_102.8.1060.4","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.68.11.815"},{"key":"2020050713014875000_102.8.1060.5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF00169099","article-title":"Long-term follow-up of central serous retinopathy in 150 patients","volume":"81","author":"Castro-Correia","year":"1992","journal-title":"Doc Ophthalmol"},{"key":"2020050713014875000_102.8.1060.6","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199911000-00005"},{"key":"2020050713014875000_102.8.1060.7","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199707000-00002"},{"key":"2020050713014875000_102.8.1060.8","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.258"},{"key":"2020050713014875000_102.8.1060.9","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181be0a83"},{"key":"2020050713014875000_102.8.1060.10","first-page":"1","article-title":"Pathogenesis of disciform detachment of the neuroepithelium","volume":"63","author":"Gass","year":"1967","journal-title":"Am J Ophthalmol"},{"key":"2020050713014875000_102.8.1060.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(02)00338-7"},{"key":"2020050713014875000_102.8.1060.12","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-154344"},{"key":"2020050713014875000_102.8.1060.13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61427"},{"key":"2020050713014875000_102.8.1060.14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318297a07a"},{"key":"2020050713014875000_102.8.1060.15","first-page":"310","article-title":"Oral eplerenone for the management of chronic central serous chorioretinopathy","volume":"8","author":"Singh","year":"2015","journal-title":"Int J Ophthalmol"},{"key":"2020050713014875000_102.8.1060.16","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00417-014-2780-6","article-title":"Spironolactone in the treatment of central serous chorioretinopathy - a case series","volume":"252","author":"Herold","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2020050713014875000_102.8.1060.17","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2147\/OPTH.S86778","article-title":"Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy","volume":"9","author":"Chin","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"2020050713014875000_102.8.1060.18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/IAE.0000000000000748","article-title":"Central serous choriretinopathy treated with mineralocorticoid\u00a0antagonists: a one-year pilot study","volume":"36","author":"Ghadiali","year":"2016","journal-title":"Retina"},{"key":"2020050713014875000_102.8.1060.19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.5.2.2","article-title":"Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy","volume":"5","author":"Daruich","year":"2016","journal-title":"Transl Vis Sci Technol"},{"key":"2020050713014875000_102.8.1060.20","doi-asserted-by":"crossref","first-page":"1084-1091","DOI":"10.1097\/IAE.0000000000001303","article-title":"Mineralocorticoid receptor antagonist treatment in bilateral chornic \u00a0central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes","volume":"37","author":"Gergely","year":"2017","journal-title":"Retina"},{"key":"2020050713014875000_102.8.1060.21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000444058","article-title":"Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis","volume":"56","author":"Kapoor","year":"2016","journal-title":"Ophthalmic Res"},{"key":"2020050713014875000_102.8.1060.22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3928\/23258160-20150422-06","article-title":"Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series","volume":"46","author":"Salz","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2020050713014875000_102.8.1060.23","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving central serous chorioretinopathy: \u00a0a randomized controlled crossover study","volume":"35","author":"Bousquet","year":"2015","journal-title":"Retina"},{"key":"2020050713014875000_102.8.1060.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-013-3001-0"},{"key":"2020050713014875000_102.8.1060.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2005.01027.x"},{"key":"2020050713014875000_102.8.1060.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30386-2"},{"key":"2020050713014875000_102.8.1060.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2007.00889.x"},{"key":"2020050713014875000_102.8.1060.28","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.72.11.829"},{"key":"2020050713014875000_102.8.1060.29","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200202000-00004"},{"key":"2020050713014875000_102.8.1060.30","first-page":"145","article-title":"Complications of argon laser retinal photocoagulation: a five-year study","volume":"16","author":"Little","year":"1976","journal-title":"Int Ophthalmol Clin"},{"key":"2020050713014875000_102.8.1060.31","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130681007"},{"key":"2020050713014875000_102.8.1060.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.04.014"},{"key":"2020050713014875000_102.8.1060.33","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/FTD.0b013e31820beb02","article-title":"Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"key":"2020050713014875000_102.8.1060.34","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.12.1453"},{"key":"2020050713014875000_102.8.1060.35","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305353"},{"key":"2020050713014875000_102.8.1060.36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/eye.2015.208","article-title":"Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis","volume":"30","author":"Lu","year":"2016","journal-title":"Eye"},{"key":"2020050713014875000_102.8.1060.37","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20324"},{"key":"2020050713014875000_102.8.1060.38","first-page":"217","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc"},{"key":"2020050713014875000_102.8.1060.39","doi-asserted-by":"crossref","unstructured":"Pichi F , Carrai P , Ciardella A , et al . Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 2016.doi:10.1007\/s10792-016-0377-2","DOI":"10.1007\/s10792-016-0377-2"},{"key":"2020050713014875000_102.8.1060.40","doi-asserted-by":"publisher","DOI":"10.1007\/BF02175443"},{"key":"2020050713014875000_102.8.1060.41","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.182121"},{"key":"2020050713014875000_102.8.1060.42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/TCRM.S50407","article-title":"The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients","volume":"9","author":"Dang","year":"2013","journal-title":"Ther Clin Risk Manag"},{"key":"2020050713014875000_102.8.1060.43","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/eye.2016.79","article-title":"The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study","volume":"30","author":"Ozkaya","year":"2016","journal-title":"Eye"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-311096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:56:11Z","timestamp":1601110571000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-311096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,31]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,19]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/bjophthalmol-2017-311096"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311096","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,31]]}}}